Prognostic value of immune biomarkers in renal clear cell carcinoma

Author:

Zhang Tong1,Duan Mingguang1,Xin Yinghui1,Liu Zhiling1,Li Kaiguo1,Liu Yuanwei1,Lv Yonghui1,Jing Haiyan2,Zhang Jie1,Huang Zhaoqin1

Affiliation:

1. Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, China

2. Department of Pathology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, China

Abstract

Abstract Objective: To analyze the expression of tumor infiltrating lymphocytes (TILs) and immune biomarkers to investigate their prognostic value in patients with Clear cell renal cell carcinoma (ccRCC). Methods: This retrospective study enrolled 152 patients who were pathologically diagnosed with ccRCC between March 2010 and December 2018 at our institute. All tumor tissue sections were collected, and immunohistochemical staining was performed to calculate the expression of CD4, CD8, PD-1 and PD-L1. Univariate and multivariate Cox proportional hazards regression analysis was used to evaluate the prognostic value of biomarkers on survival. The association of clinicopathological variables and biomarkers were tested by Chi-squared test, Fisher’s exact test or Student’s t-test. Results: In univariable analysis, increased tumor-infiltrating of CD8+ T cells and PD-L1 positive cells were associated with poor overall survival (OS) and disease-free survival (DFS). In multiple analysis, increased CD8+T cells was an independent prognostic factor for poor DFS (p=0.009) and increased PD-L1 was independent prognostic factors for poor OS (p=0.030). Conclusion: This study showed some TILs and biomarkers can provide some prognostic data for clinical subsequent therapy for patients with ccRCC.

Publisher

Research Square Platform LLC

Reference31 articles.

1. Bahadoram S, Davoodi M, Hassanzadeh S, et al. Renal cell carcinoma: an overview of the epidemiology, diagnosis, and treatment. Volume 39. G Ital Nefrol; 2022. 3.

2. Roldan FL, Lozano JJ, Ingelmo-Torres M et al. Clinicopathological and Molecular Prognostic Classifier for Intermediate/High-Risk Clear Cell Renal Cell Carcinoma. Cancers (Basel), 2021. 13(24).

3. Diana P, Klatte T, Amparore D et al. Screening programs for renal cell carcinoma: a systematic review by the EAU young academic urologists renal cancer working group.World J Urol, 2022.

4. Clinical T1a Renal Cell Carcinoma, Not Always a Harmless Disease-A National Register Study;Almdalal T;Eur Urol Open Sci,2022

5. Ljungberg B, Albiges L, Abu-Ghanem Y et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. Eur Urol, 2022.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3